Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 225,206,852 papers from all fields of science
Search
Sign In
Create Free Account
FH 510
Known as:
9H-Carbazole-4-ethanamine, 5,8-dimethyl-N,N-dipropyl-, monohydrochloride
, FH-510
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
2 relations
Broader (2)
Carbazoles
Propylamines
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Review
1994
Review
1994
[Sigma-ligands for new therapeutic drugs].
M. Muramatsu
,
S. Okuyama
,
M. Tanaka
Nihon yakurigaku zasshi. Folia pharmacologica…
1994
Corpus ID: 23639226
Compounds that show their pharmacological actions via specific receptors are considered potential candidates for new drugs…
Expand
1993
1993
FH-510, a potent and selective ligand for rat brain sigma recognition sites.
M. Tanaka
,
S. Chaki
,
Y. Imagawa
,
S. Okuyama
,
M. Muramatsu
,
S. Otomo
European Journal of Pharmacology
1993
Corpus ID: 29475358
FH-510 (5,8-dimethyl-4-(2-di-n-propylaminoethyl)carbazol) is a potent ligand for sigma ligand binding sites in rat brain…
Expand
1993
1993
Discrimination of (+)-3-PPP sites from DTG sites by FH-510, a novel potent sigma ligand, in rat brain.
S. Chaki
,
M. Tanaka
,
M. Muramatsu
,
S. Otomo
European Journal of Pharmacology
1993
Corpus ID: 4619964
The effect of 5,8-dimethyl-4-(2-di-n-propylaminoethyl)carbazol monohydrochloride (FH-510) on the binding of sigma ligands such as…
Expand
1993
1993
Binding of [3H]FH-510 to sigma ligand recognition sites in guinea-pig brain membranes.
M. Tanaka
,
S. Kaku
,
M. Muramatsu
,
S. Otomo
European Journal of Pharmacology
1993
Corpus ID: 4521202
We examined the characteristics of the binding of radiolabeled 5,8-dimethyl-4-(2-di-n-propylaminoethyl)carbazol monohydrochloride…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE